West Pharmaceutical Services Balance Sheet Health
Financial Health criteria checks 6/6
West Pharmaceutical Services has a total shareholder equity of $2.9B and total debt of $206.8M, which brings its debt-to-equity ratio to 7.2%. Its total assets and total liabilities are $3.8B and $948.5M respectively. West Pharmaceutical Services's EBIT is $710.5M making its interest coverage ratio -37.4. It has cash and short-term investments of $853.9M.
Key information
7.2%
Debt to equity ratio
US$206.80m
Debt
| Interest coverage ratio | -37.4x |
| Cash | US$853.90m |
| Equity | US$2.88b |
| Total liabilities | US$948.50m |
| Total assets | US$3.83b |
Recent financial health updates
Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12
West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31West Pharmaceutical Services (NYSE:WST) Seems To Use Debt Rather Sparingly
Oct 25Recent updates
West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price
Mar 30Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12Why West Pharma Is Far From Done
Feb 28West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 20West Pharmaceutical Services: Still Too Expensive After The Recent Drop
Feb 20What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?
Jan 10West Pharmaceutical: Great Business, Not So Great Valuation
Jan 08What West Pharmaceutical Services, Inc.'s (NYSE:WST) P/E Is Not Telling You
Dec 18West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27West Pharmaceutical Services: The Run Might Be Over
Oct 18Is West Pharmaceutical Services, Inc. (NYSE:WST) Potentially Undervalued?
Sep 24Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08What Is West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Doing?
Jun 26West Pharmaceutical: Hard To Justify The Price
May 26Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16At US$330, Is It Time To Put West Pharmaceutical Services, Inc. (NYSE:WST) On Your Watch List?
Mar 20West Pharmaceutical Services' (NYSE:WST) Soft Earnings Don't Show The Whole Picture
Feb 28West Pharmaceutical Q4 2022 Earnings Preview
Feb 15West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive
Dec 19West Pharmaceutical declares $0.19 dividend
Dec 13Why West Pharmaceutical Services, Inc. (NYSE:WST) Could Be Worth Watching
Nov 29West Pharmaceutical Q3 2022 Earnings Preview
Oct 26West Pharmaceutical Services (NYSE:WST) Seems To Use Debt Rather Sparingly
Oct 25West Pharmaceutical Services: Shares Need To Get Cheaper To Make Sense
Oct 02Is West Pharmaceutical Services, Inc. (NYSE:WST) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 14Is There Now An Opportunity In West Pharmaceutical Services, Inc. (NYSE:WST)?
Aug 31Do West Pharmaceutical Services' (NYSE:WST) Earnings Warrant Your Attention?
Aug 18West Pharmaceutical Q2 Non-GAAP EPS, revenue beats
Jul 28Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Jul 27West Pharmaceutical Services: A Great Business At A Lofty Price
Jul 06West Pharmaceutical Services, Inc. (NYSE:WST) Shares Could Be 32% Above Their Intrinsic Value Estimate
Jun 09Should You Think About Buying West Pharmaceutical Services, Inc. (NYSE:WST) Now?
May 20Does West Pharmaceutical Services (NYSE:WST) Deserve A Spot On Your Watchlist?
May 05Healthy Dividends: Organic Growth Points North For West Pharmaceutical Services
Apr 27We Think West Pharmaceutical Services (NYSE:WST) Can Manage Its Debt With Ease
Apr 22Financial Position Analysis
Short Term Liabilities: WST's short term assets ($1.9B) exceed its short term liabilities ($671.8M).
Long Term Liabilities: WST's short term assets ($1.9B) exceed its long term liabilities ($276.7M).
Debt to Equity History and Analysis
Debt Level: WST has more cash than its total debt.
Reducing Debt: WST's debt to equity ratio has reduced from 14% to 7.2% over the past 5 years.
Debt Coverage: WST's debt is well covered by operating cash flow (375.5%).
Interest Coverage: WST earns more interest than it pays, so coverage of interest payments is not a concern.